Viking Therapeutics Q2 2024 GAAP EPS $(0.20) Beats $(0.27) Estimate
Portfolio Pulse from Benzinga Newsdesk
Viking Therapeutics (NASDAQ:VKTX) reported a Q2 2024 GAAP EPS of $(0.20), beating the analyst consensus estimate of $(0.27) by 25.93%.
July 24, 2024 | 8:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viking Therapeutics reported a Q2 2024 GAAP EPS of $(0.20), which is better than the analyst consensus estimate of $(0.27). This positive earnings surprise could boost investor confidence and potentially lead to a short-term increase in the stock price.
The better-than-expected earnings report indicates that Viking Therapeutics is performing better than analysts anticipated, which is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100